{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:02:29Z","timestamp":1787014949867,"version":"build-2736575974"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T00:00:00Z","timestamp":1294790400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Paricalcitol is more effective than calcitriol in hemodialysis patients (HD) with secondary hyperparathyroidism (SHPT), but it is not effective in some of them. We have investigated the relationship between paricalcitol responsiveness and parathyroid gland (PTG) size. Thirty HD with SHPT treated previously with calcitriol for at least 6 months were switched to paricalcitol (1:4 conversion ratio). Parathyroid gland number and size (maximum longitudinal diameter [MLD] of largest PTG) was measured by ultrasonography. Patients were divided into 2 groups: group A (MLD \u22649.0\u2003mm [17 HD]); and group B (MLD &gt;9.0\u2003mm [13 HD]). They were defined responder if both the last 2 monthly determinations of inhibit parathyroid hormone (iPTH) were within the target (&lt;300\u2003pg\/mL) according to National Kidney Foundation Kidney Disease Outcomes Quality Initiative recommendations. Twenty\u2010six and 20 HD completed 6\u2010month and 12\u2010month paricalcitol therapy, respectively. After 6 months of paricalcitol treatment, 23.5% HD of group A and 7.7% of group B were responders. At 12 months, 41.2 % of group A and 7.7% of group B were responders. Throughout paricalcitol therapy, serum calcium and phosphorus concentrations slightly increased in all HD but more significantly in group B. The baseline iPTH and MLD of the largest PTG were significantly correlated with final iPTH levels. Paricalcitol is more effective than calcitriol in SHPT, but the responsiveness to paricalcitol and hypercalcemia are related to PTG size. The measurement of MLD by ultrasonography may be useful for predicting responsiveness to paricalcitol, avoiding an unnecessary and expensive therapy.<\/jats:p>","DOI":"10.1111\/j.1542-4758.2010.00514.x","type":"journal-article","created":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T01:47:55Z","timestamp":1294796875000},"page":"69-78","source":"Crossref","is-referenced-by-count":17,"title":["Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size"],"prefix":"10.1111","volume":"15","author":[{"given":"Carlo","family":"VULPIO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"MARESCA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"DISTASIO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"CACACI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"PANOCCHIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"LUCIANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"BOSSOLA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.61.s80.26.x"},{"key":"e_1_2_5_3_2","first-page":"369","article-title":"Management of secondary hyperparathyroidism","volume":"23","author":"Moe SM","year":"2003","journal-title":"The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product"},{"key":"e_1_2_5_4_2","first-page":"S143","article-title":"Control of uremic bone disease","volume":"61","author":"Slatopolsky E","year":"2002","journal-title":"Role of vitamin D analogs"},{"key":"e_1_2_5_5_2","first-page":"1981","article-title":"Receptor activator selectivity in the treatment of secondary hyperparathyroidism","volume":"67","author":"Brancaccio D","year":"2007","journal-title":"Understanding the differences among therapies"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.380"},{"key":"e_1_2_5_7_2","first-page":"S57","article-title":"Paricalcitol dosing according to body weight or severity of hyperparathyroidism","volume":"38","author":"Martin KJ","year":"2001","journal-title":"A double-blinded, multicenter, randomized study"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9808142"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000266204"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022536"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh123"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28114"},{"key":"e_1_2_5_13_2","first-page":"315","article-title":"A long\u2010term, multicenter study of the efficacy and safety of paricalcitol in end\u2010stage renal disease","volume":"56","author":"Lindberg J","year":"2001","journal-title":"Clin Nephrol"},{"key":"e_1_2_5_14_2","first-page":"S51","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients","volume":"83","author":"Sprague SM","year":"2001","journal-title":"Comparison of paricalcitol with calcitriol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00878.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188261"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.483"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70199-5"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.10.2398"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000116875"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116720"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2008.00615.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg451"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2006.00364.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"e_1_2_5_26_2","first-page":"S64","article-title":"Paricalcitol therapy for secondary hyperparathyroidism in patients on hemodialysis previously treated with calcitriol","volume":"70","author":"Mittmann N","year":"2006","journal-title":"A single-center crossover study"},{"key":"e_1_2_5_27_2","first-page":"59","article-title":"Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients","volume":"22","author":"Capuano A","year":"2009","journal-title":"J Nephrol"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0204-5"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.04.060"},{"key":"e_1_2_5_30_2","first-page":"1","article-title":"Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth","volume":"4","author":"Taniguchi M","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.223"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21320"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1542-4758.2010.00514.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1542-4758.2010.00514.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:05:44Z","timestamp":1697385944000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1542-4758.2010.00514.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1542-4758.2010.00514.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1542-4758.2010.00514.x","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}